Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA (opens original article in a new tab)

Organon Canada and Henlius expanded access to denosumab treatments in Canada with the launch of biosimilars BILDYOS and TUZEMTY, offering alternatives to PROLIA and XGEVA for osteoporosis and cancer-related bone conditions.

• Organon Canada and Henlius launched biosimilars BILDYOS and TUZEMTY for denosumab treatments in Canada.
• The biosimilars are alternatives to PROLIA and XGEVA, used for osteoporosis and cancer-related bone events.
• The launch aims to improve access to bone-care treatments and reduce healthcare costs.